Health Condition 1: null- Lung Cancer Patients
Conditions
Interventions
Intervention1: Not Applicable: Not Applicable
Control Intervention1: Not Applicable: Not Applicable
Sponsors
None listed
Eligibility
Inclusion criteria
Inclusion criteria: We will include all patients whose details have been entered in the prospectively maintained medical oncology database of SCLC patients with PS >2 who were offered chemotherapy from 2010 onwards (to date).
Exclusion criteria
Exclusion criteria: None
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine the percentage of patients who had an improvement in disease-attributable symptoms.Timepoint: At first followup after chemotherapy, i.e 7-days after chemotherapy and before cycle 2 of chemotherapy, i.e. at 3 weeks after cycle 1 of chemotherapy, and at the conclusion of chemotherapy (18 weeks after cycle 1 of chemotherapy) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To determine the percentage of patients who were able to receive subsequent standard course of chemotherapy. 2. Overall survival 3. Progression-free survival 4. Response rate to first line chemotherapy 5. To evaluate the factors that affected toxicity. 6. To evaluate the factors that affected survival. Timepoint: 1. 21 weeks after date of start of chemotherapy 2 Death 3. AT disease progression 4,5 & 6- After 9 weeks & after 21 weeks | — |
Countries
India
Contacts
Public ContactDr Vanita Noronha
Tata Memorial Hospital
Outcome results
None listed